News about Market

Glenmark Launches Epinephrine Injection Multi-Dose Vial

Glenmark has introduced its Epinephrine Injection USP, 1?mg/mL, 30?mg/30?mL multiple-dose vial, which is bioequivalent and therapeutically equivalent to the reference drug by BPI Labs, LLC (NDA 205029), offering a reliable alternative for patients and healthcare providers.

Market | 23/12/2025 | By News Bureau |  225

Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class CKD Treatments

The collaboration will focus on accelerating the development of first-in-class oral small-molecule therapies for chronic kidney disease and other conditions, leveraging Rectify’s ABCC6-targeting platform designed to reduce pathological calcification.

Market | 23/12/2025 | By News Bureau |  237

Alvotech Announces European Launch of Golimumab Biosimilar via Advanz Pharma

Alvotech has announced the European launch of AVT05, the first biosimilar to Simponi (golimumab), through its partner Advanz Pharma, following a tender award from NHS England in the UK to support market introduction.

Market | 22/12/2025 | By News Bureau |  165

Emcure Launches Poviztra to Broaden Access to Weight Management Therapy

Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.

Market | 22/12/2025 | By News Bureau |  403

Samsung Biologics Expands US Manufacturing with HGS Acquisition from GSK

Samsung Biologics has acquired Human Genome Sciences (HGS) from GSK, securing its first US-based manufacturing site and strengthening its global supply network. The company plans further investments to expand capacity and capabilities at the facility, reinforcing its long-term commitment to the US biopharmaceutical manufacturing ecosystem.

Market | 22/12/2025 | By News Bureau |  400

Jacobio Pharma Signs Global Licensing Deal with AstraZeneca for Pan-KRAS Drug

Under the agreement, Jacobio will receive USD 100 million upfront and is eligible for up to USD 1.915 billion in development and commercial milestones, along with tiered royalties on ex-China sales, while AstraZeneca will lead all ex-China development, regulatory and commercial activities for JAB-23E73.

Market | 22/12/2025 | By News Bureau |  301

IN8bio Prices Private Placement of up to USD 40.2 Million

IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.

Market | 20/12/2025 | By News Bureau |  218

Symbiotec Pharmalab Files Draft Papers to Raise INR 2,180 Crore via IPO

Symbiotec Pharmalab Ltd has filed draft red herring prospectus papers with the Securities and Exchange Board of India to raise INR 2,180 crore through an initial public offering.

Market | 20/12/2025 | By Darshana |  297

Cue Biopharma Prices USD 10 Million Public Offering

Cue Biopharma has priced a USD 10 million public offering, with gross proceeds expected to be approximately USD 10 million before underwriting discounts, commissions, and other offering-related expenses.

Market | 20/12/2025 | By News Bureau |  183

Ambros Therapeutics Launches with USD 125 Million Series A to Advance CRPS Therapy

Ambros Therapeutics has launched with a USD 125 million Series A financing to advance neridronate for Complex Regional Pain Syndrome Type 1, supported by multiple FDA designations and an oversubscribed round led by RA Capital Management and Patient Square Capital, with a pivotal phase III trial planned for early 2026.

Market | 19/12/2025 | By News Bureau |  642